Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
Get Alerts APLS Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 3:40 p.m. PT.
The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.
About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:Meredith Kaya[email protected]617.599.8178
Source: Apellis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Health Institute Announces Heal Your Cells, a New Book by Dr. Josh Axe and Dr. Will Cole on Cellular Health and Healthy Aging
- Kevin Wheeler to Retire as Executive Chairman; President and CEO Stephen Shafer Named Chairman
- SEACOR Marine Acknowledges Receipt of Letter by Shareholder
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share